Background: Portal hypertension is a major complication of chronic liver diseases, leading to serious issues such as esophageal variceal bleeding. The increase in portal vein pressure is driven by both an organic component and a functional component, including tonic contraction of hepatic stellate cells. These processes result in a pathological rise in intrahepatic vascular resistance, stemming from partial impairment of hepatic microcirculation, which is further exacerbated by abnormalities in extrahepatic vessels, including increased portal blood flow. Objectives: This review aims to provide a comprehensive overview of the evolving pharmacological therapies for portal hypertension, with consideration and discussion of pathophysiological mechanisms, clinical complications, and pharmacogenetic considerations, highlighting potential directions for future research. Methods: A review of recent literature was performed to evaluate current knowledge and potential therapeutic strategies in portal hypertension. Results: For over 35 years, non-selective beta-blockers have been the cornerstone therapy for portal hypertension by reducing portal vein inflow as an extrahepatic target, effectively preventing decompensation and variceal hemorrhages. However, since not all patients exhibit an adequate response to non-selective beta-blockers (NSBBs), and some may not tolerate NSBBs, alternative or adjunctive therapies that enhance the effects of NSBBs on portal pressure are being investigated in preclinical and early clinical studies. Conclusions: A better understanding of pharmacogenetic factors and pathophysiological mechanisms could lead to more individualized and effective treatments for portal hypertension. These insights highlight potential directions for future research.
Introduction: The prevalence of preoperative anemia is highest in the group of colorectal cancer (CRC) patients and may reach over 75%. The prevalence of anemia in CRC patients increases even further following surgery. Approximately 75-80% of anemic CRC patients present with absolute or functional iron deficiency (IDA). Preoperative anemia constitutes an independent risk factor for allogeneic blood transfusion (ABT), postoperative complications, prolonged length of hospital stay, and increased mortality. Allogeneic blood transfusion is itself associated with increased morbidity and mortality.Aim: The aim of this review article was to present the pathophysiology and the current approach to diagnosis and treatment of preoperative IDA in CRC patients.Material and methods: Extensive search of medical literature databases was performed (Pubmed, Embase). The key words that were used were as follows: colorectal cancer, colorectal surgery, iron-deficiency, iron-deficiency anemia, intravenous iron, Patient Blood Management.Results: There are several laboratory parameters that can be used for IDA diagnosis, however the simplest and cost-effective is reticulocyte hemoglobin equivalent. Pathophysiologic features of IDA in CRC patients favor treatment with intravenous, as oppose to oral, iron formulations. Applying Patient Blood Management strategies minimizes the exposure to ABT.Conclusions: Preoperative IDA is highly prevalent among CRC patients. Preoperative anemia is an independent risk factor for ABT, increased morbidity and mortality, as well as prolonged hospital length of stay. The same negative consequences are associated with ABT. Therefore preoperative IDA in CRC patient needs to be screened for, diagnosed, and treated before surgery. Effective treatment of preoperative IDA in CRC patients is with intravenous iron formulations. Allogeneic blood transfusion should be the treatment of last resort due to risk of negative clinical consequences, including increased rate of cancer recurrence.
10 November 2025 in The Journal of Cardiovascular Aging
Myocardial infarction (MI) and age-related cardiac remodeling remain major causes of morbidity and mortality worldwide. Because the adult heart has only limited regenerative capacity, extracellular vesicles (EVs) have emerged as promising acellular mediators of tissue repair, with the potential to mitigate both ischemic injury and age-associated decline. Preclinical studies demonstrate that EVs derived from stem and progenitor cells exert anti-apoptotic, anti-fibrotic, anti-inflammatory, and pro-angiogenic effects. In aged hearts, EVs can help restore metabolic homeostasis, attenuate pro-senescent signaling, and improve functional resilience. Early-phase clinical trials suggest that EV-based or EV-enriched products are feasible and safe, although evidence of efficacy remains limited. This review synthesizes current mechanistic insights into EV-mediated regulation of inflammation, fibrosis, angiogenesis, oxidative and ferroptotic stress, and cellular senescence, underscoring the therapeutic potential of EVs in cardiac regeneration - particularly in older patients with impaired endogenous repair. Importantly, it uniquely integrates the dual roles of EVs in both myocardial infarction repair and cardiac aging, thereby addressing a critical gap in the literature. By linking mechanisms of post-infarction regeneration with age-related cardiac decline, we outline the translational challenges and opportunities of EV-based therapies. Further advances in EV engineering, targeting, dosing, potency assays, and standardization will be essential for successful clinical translation.
Background: Annually millions of platelet concentrate (PC) are transfused worldwide. The decision regarding PC transfusion is often complex; therefore, the implementation of a hospital programme designed to streamline and facilitate the decision‐making process is beneficial. Such a programme helps standardise transfusion practices, ensures that PCs are used appropriately, while also optimising patient outcomes.Objectives: The study aimed to analyse the impact of a new hospital utilisation improvement programme on PC transfusions.Methods/Materials: We performed a retrospective analysis of all PC transfusions in adult patients hospitalised in our large academic medical centre. The analysed time covered 12‐month periods before and after the introduction of the program, which was based on the most recent clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies. Indications for PC transfusion were divided into prophylactic and therapeutic. The new program was made available on the hospital intranet, obligatory e‐learning was required from all clinical and laboratory personnel, and a computerised physician order entry was modified.Results: The transfusion rate in the whole analysed period was 0.17%. The median pre‐transfusion platelet count before and after implementation of the programme was 28 (IQR 15.0–50.0) and 24 (IQR 12.0–42.0) × 109/L, respectively. Percentage of therapeutic transfusions increased from 46.7% to 57.7%. Overall the appropriateness of transfusions went up from 48.4% to 59.9%, and was higher for therapeutic (70.2% vs. 60.0%) than prophylactic (45.8% vs. 38.3%) transfusions.Conclusion: Simple hospital utilisation improvement programme, adjusted to the local population and backed by e‐learning and modification of a computerised physician order entry, can lead to a more restrictive use of PC transfusions in patients with thrombocytopenia.
Background/Objectives: Myocardial ischemia–reperfusion injury (MIRI) remains an ever-growing threat in the field of cardiology, as it has become a major risk factor for unfavorable outcomes following reperfusion therapies. Oxidative stress and inflammation remain the key pathophysiological mechanisms underlying MIRI, and the presently available treatments fail to prevent this process effectively. This systematic review aimed to summarize and critically assess the latest preclinical research (2020–2026) on nanocarrier-based interventions targeting oxidative stress in MIRI, highlighting the potential of the new nanostructures in cardioprotection. Methods: A total of 24 studies meeting the PRISMA criteria have been found through a literature search of PubMed, Embase, and Web of Science databases published between 2020 and 2026. The studies eligible for inclusion had focused on the efficacy of nanocarrier-based interventions in preclinical studies of MIRI. Results: Of the 24 included studies, all investigated nanocarrier-based interventions in preclinical models of MIRI. In vitro, ex vivo, and in vivo models were diverse, with most studies being a combination of both in vitro and in vivo models. Commonly studied were lipid-based nanocarriers, polymeric nanoparticles, and biomimetic nanocarriers. Across studies assessed for this review, treatments with nanocarriers were seen to suppress inflammatory and oxidative stress pathways, with a few studies showing a suppression of cardiomyocyte apoptosis. Cardiac function was restored as determined by echocardiography analyses or ex vivo models of the myocardium, thus validating that the nanocarrier-mediated therapies are effective against MIRI. Conclusions: The analyzed preclinical studies indicate that the described therapies could provide a promising basis for future clinical trials in the treatment of MIRI, provided their safety and efficacy are confirmed in clinical trials.